Proven noninvasive technology

Cell-free DNA (cfDNA) is analyzed from a maternal blood sample to assess the pregnancy for common chromosome aneuploidies, including trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome abnormalities. This noninvasive screen offers providers and their patients accurate information about the risk for these conditions during pregnancy, as early as 10 weeks’ gestation.

The Innatal Prenatal Screen utilizes massively parallel sequencing (MPS) across the whole genome. This method sequences short fragments of DNA, creating millions of reads that are then mapped to the reference genome. The reads are counted to determine whether the sample has extra or missing reads from a particular chromosome. Abnormal dosage indicating aneuploidy is presumed to be fetal in origin. In rare circumstances, there is an alternative explanation.

Progenity has upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry, demonstrating higher sensitivities than previous versions of the test. Fetal fraction is determined for each sample using a proprietary algorithm. Previous performance strengths have been maintained, including low failure rates and quick results.

In-depth verification and validation testing of the Innatal Prenatal Screen assay, using >1000 samples, was conducted as prescribed by multiple peer-reviewed guidelines.1,2,3